Background/Aims: Glucagon-like peptide-1 (GLP-1) inhibits food intake in animals and humans. Whether GLP-1 interacts with other satiety signals to modulate food intake is unknown. We investigated therefore in healthy volunteers the potential interactions of GLP-1 with signals from the stomach in regulating food intake. Methods: Three sequential, double-blind, crossover studies were performed in male subjects: (1) 12 subjects underwent four experiments (preloads) 20 min before meal intake; (2) 12 volunteers received intravenous (i.v.) GLP-1 (0.9 pmol/kg/min) or saline; (3) subjects received i.v. GLP-1 or saline (control) together with a preload of either 400 ml water or 400 ml protein shake. The effect of these treatments on food intake and feelings of hunger was quantified. Subjects were free to eat and drink as much as they wished. Results: GLP-1 induced a reduction in food and calorie intake (p < 0.005) compared to controls. If combined with a protein preload, the inhibitory effect of GLP-1 on food intake was markedly increased (p < 0.001). Furthermore, a decrease in hunger feelings and an increase in satiety feelings was documented. Conclusion: GLP-1 interacts with signals from the stomach to modulate energy intake in humans. The signal is only initiated by nutrient-based distension, but not with gastric distension of the fundus alone.

1.
Azpiroz F, Malagelada JR: Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. Gastroenterology 1987;92:934&ndash;943.
[PubMed]
2.
Azpiroz F, Malagelada JR: Physiological variations in canine gastric tone measured by an electronic barostat. Am J Physiol 1985;248:G229&ndash;G237.
3.
Byrne MM, Goke B: Human studies with glucagon-like peptide-1: potential of the gut hormone for clinical use. Diabet Med 1996;13:854&ndash;860.
[PubMed]
4.
Drucker DJ: Glucagon-like peptides. Diabetes 1998;47:159&ndash;169.
[PubMed]
5.
Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515&ndash;520.
[PubMed]
6.
Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A: The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 2000;24:288&ndash;298.
[PubMed]
7.
Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541&ndash;R1544.
[PubMed]
8.
Gutzwiller JP, Drewe J, Ketterer S, Hildebrand P, Krautheim A, Beglinger C: Interaction between CCK and a preload on reduction of food intake is mediated by CCK1 receptors in humans. Am J Physiol 2000;279:R189&ndash;R195.
9.
Gutzwiller JP, Goeke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C: Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999;44:81&ndash;86.
[PubMed]
10.
Verdich C, Flint A, Gutzwiller JP, N&auml;slund E, Hellstr&ouml;m PM, Long SJ, Morgan LM, Beglinger C, Holst JJ, Astrup A: A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on subsequent ad libitum energy intake in humans. J Clin Endocrinol Meta 2001;86:4382&ndash;4389.
[PubMed]
11.
Herrmann C, Goke R, Richter G, Fehmann HC, Arnold, Goke B: Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117&ndash;126.
[PubMed]
12.
Holst JJ: Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential. Curr Med Chem 1999;6:1005&ndash;1017.
[PubMed]
13.
Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663&ndash;1670.
[PubMed]
14.
Layer P, Holst JJ, Grandt D, Goebell H: Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995;40:1074&ndash;1082.
[PubMed]
15.
Matzinger D, Gutzwiller JP, Drewe, Orban JA, Engel R, D&rsquo;Amato M, Rovati L, Beglinger C: Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans. Am J Physiol 1999;277:R1718&ndash;R1724.
16.
Muurahainen N, Kissileff HR, Derogatis AJ, Pi-Sunyer FX: Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav 1988;44:645&ndash;649.
[PubMed]
17.
Muurahainen NE, Kissileff HR, Lachaussee JF, Pi-Sunyer X: Effect of a soup preload on reduction of food intake by cholecystokinin in humans. Am J Physiol 1991;260:R672&ndash;R680.
18.
Naslund E, Barkeling B, King, NM, Gutniak JE, Blundell JJ, Holst S, Rossner, Hellstrom PM: Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999;23:304&ndash;311.
[PubMed]
19.
Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM: GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910&ndash;R916.
20.
Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM: Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998;68:525&ndash;530.
[PubMed]
21.
Nauck M: Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabet Med 1996;13:S39&ndash;S43.
22.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741&ndash;744.
[PubMed]
23.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273:E981&ndash;E988.
24.
Rouillon JM, Azpiroz F, Malagelada JR: Reflex changes in intestinal tone: relationship to perception. Am J Physiol 1991;261:G280&ndash;G286.
25.
Rouillon JM, Azpiroz F, Malagelada JR: Sensorial and intestinointestinal reflex pathways in the human jejunum. Gastroenterology 1991;101:1606&ndash;1612.
[PubMed]
26.
Smith GP: Introduction to the reviews on peptides and the control of food intake and body weight. Neuropeptides 1999;33:323&ndash;328.
[PubMed]
27.
Welch I, Saunders K, Read NW: Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. Gastroenterology 1985;89:1293&ndash;1297.
[PubMed]
You do not currently have access to this content.